风湿免疫科医生临床经验评估临床可疑关节痛患者进展为类风湿关节炎风险的准确性
本研究纳入501例来自Leiden CSA队列和TREAT EARLIER试验安慰剂组的临床可疑关节痛(CSA)患者,比较风湿免疫科医生基于临床经验估计的1年内进展为类风湿关节炎(RA)风险与EULAR/ACR风险分层标准的判别能力。结果显示,临床经验估计的AUC为0.64(95%CI 0.55-0.73),而EULAR/ACR标准为0.91(95%CI 0.87-0.95),且临床经验主要高估了RA进展风险。
要点
- 风湿免疫科医生临床经验估计CSA患者1年内进展为RA风险的判别能力仅为中等(AUC 0.64)。
- EULAR/ACR风险分层标准在同一人群中判别能力优秀(AUC 0.91),显著优于临床经验。
- 临床经验估计的RA风险较实际观察到的进展率整体偏高,存在高估。
核心结论
- 风湿免疫科医生基于临床经验评估CSA患者进展为RA的风险不准确,主要表现为风险高估。
- 当风险信息对临床或治疗决策有影响时,应优先使用EULAR/ACR风险分层标准而非单纯临床经验。
研究设计与样本
- 研究纳入501例来自Leiden CSA队列和TREAT EARLIER试验安慰剂组的CSA患者。
- 基线时风湿免疫科医生根据病史、体格检查和实验室结果,以0-10数字评定量表估计RA风险。
- 使用基线数据计算EULAR/ACR风险分层标准(不含影像学),比较两者对1年内RA进展(2010标准)的判别能力。
主要发现
- 风湿免疫科医生基于经验估计的RA风险均值为5(SD 1.6),0-10量表。
- 临床经验估计的AUC为0.64(95%CI 0.55-0.73),对进展与未进展RA患者的区分能力为中等。
- 临床经验估计的RA风险较实际观察到的进展率整体偏高。
- EULAR/ACR风险分层标准在同一患者中AUC为0.91(95%CI 0.87-0.95)。
关键数值与推荐
- 临床经验估计RA风险的AUC为0.64(95%CI 0.55-0.73)。
- EULAR/ACR风险分层标准(不含影像学)的AUC为0.91(95%CI 0.87-0.95)。
- 风湿免疫科医生经验估计的RA风险均值为5(SD 1.6),采用0-10数字评定量表。
临床怎么用
- 在CSA患者中评估进展为RA的风险时,不应仅依赖临床经验判断。
- 当风险信息具有临床或治疗意义时,建议使用EULAR/ACR风险分层标准进行风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Clinical expertise is paramount in medical decision-making. In the setting of arthralgia, this expertise is highly relevant in differentiating clinically suspect arthralgia (CSA) from other musculoskeletal symptoms. However, it remains unclear whether rheumatological expertise is also reliable in estimating the risk of progression to rheumatoid arthritis (RA) in CSA patients. Using clinical expertise is more time-efficient than applying criteria, such as the European Alliance of Associations for Rheumatology/American College of Rheumatology (EULAR/ACR) risk stratification criteria for RA development. This study assessed the accuracy of RA-risk estimation based on rheumatologists' clinical expertise and compared this to these criteria. METHODS: 501 CSA patients from the Leiden CSA cohort and placebo arm of the TREAT EARLIER trial were studied. At baseline, rheumatologists estimated RA risk (0-10 Numeric Rating Scale) informed by history, physical examination and laboratory results. The EULAR/ACR risk stratification criteria (without imaging) were calculated using baseline data. The outcome was RA development (2010 criteria) within 1 year, and the discrimination was compared. RESULTS: Based on their expertise, rheumatologists estimated the risk of RA as a mean of 5 (SD 1.6) on a 0-10 scale. With an area under the curve (AUC) of 0.64 (95% CI 0.55 to 0.73), patients who did or did not develop RA were moderately differentiated. The RA risk was mainly overestimated compared with observed progression rates. In comparison, the EULAR/ACR risk stratification criteria in the same patients yielded an AUC of 0.91 (95% CI 0.87 to 0.95). CONCLUSIONS: Rheumatologists' clinical expertise is inaccurate in assessing the risk of developing RA in patients with CSA, due to risk overestimation. This may support the use of established criteria when risk information has clinical or therapeutic implications. TRIAL REGISTRATION NUMBER: NTR4853-trial-NL4599.
引用
- Claassen S, van Steenbergen HW, van der Helm-Van Mil AHM, et al. Rheumatologist's expertise in estimating risk of developing rheumatoid arthritis in patients with clinically suspect arthralgia: what is the value? RMD Open. 2026. PMID: 41720598. doi:10.1136/rmdopen-2025-006473
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。